0.481

2.12% 0.01

After Hours: .48 -0.001 -0.21%

Estrella Immunopharma Inc (ESLA)

Overview News Price History Discussions Forecast

Estrella Immunopharma Inc stock is traded at $0.481, with a volume of 27,798. It is up +2.12% in the last 24 hours and down -34.33% over the past month. Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.

Previous Close:

$0.471

Open:

$0.471

24h Volume:

27,798

Relative Volume:

0.70

Market Cap:

$20.92M

Revenue:

Net Income/Loss:

$-13.25M

P/E Ratio:

-1.3614

EPS:

-0.3533

Net Cash Flow:

$-8.02M

1W Performance:

-9.07%

1M Performance:

-34.33%

6M Performance:

-50.93%

1Y Performance:

-58.17%

1-Day Range:

$0.467

$0.4999

1-Week Range:

$0.4605

$0.58

52-Week Range:

$0.4605

$3.15

Estrella Immunopharma Inc Stock (ESLA) Company Profile

Name

Estrella Immunopharma Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

(510) 318-9098

Address

5858 HORTON STREET, SUITE 370, EMERYVILLE

Employee

Twitter

Next Earnings Date

2026-05-13

Latest SEC Filings

ESLA's Discussions on Twitter

Compare ESLA vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ESLA Estrella Immunopharma Inc	0.481	20.92M	0	-13.25M	-8.02M	-0.3533
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Estrella Immunopharma Inc Stock (ESLA) Latest News

Sep 20, 2026

Estrella Immunopharma Warrant (ESLAW) Trades Flat at $0.07 as Range Holds TightAI Trade Signals - dars.gov.et

Sep 20, 2026

Sep 08, 2026

Estrella Immunopharma Faces Nasdaq Listing Compliance Challenge - TipRanks

Sep 08, 2026

Estrella Immunopharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Sep 08, 2026

Aug 26, 2026

Estrella (ESLA) Earnings Reading: EPS Falls Short of Its Estimate in the Current Update; Market Response: The Stock Records a 1.20% Increase in the Latest SessionRevenue Growth Outlook - dars.gov.et

Aug 26, 2026

ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial - Yahoo Finance

Aug 26, 2026

Aug 21, 2026

Estrella Immunopharma Receives Nasdaq Minimum Bid Price Notice - TipRanks

Aug 21, 2026

Aug 20, 2026

ARMISTICE CAPITAL, LLC Reduces Stake in Estrella Immunopharma Inc (ESLA) by Nearly Half - GuruFocus

Aug 20, 2026

Aug 18, 2026

Estrella Immunopharma Inc. (NASDAQ: ESLA) Share Price, ESLA Stock News, ESLA Share Price & Updates - Kalkine

Aug 18, 2026

Aug 16, 2026

Estrella Immunopharma (ESLA) Holds Ground at $0.72 as Immunotherapy Pipeline Takes Center StageLong Short Pair - vinanet.vn

Aug 16, 2026

Price to earnings forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView

Aug 16, 2026

Aug 15, 2026

Estrella Immunopharma (ESLA) Holds at $0.72 as Support Firms in Quiet Micro-Cap SessionIchimoku TK Cross - vinanet.vn

Aug 15, 2026

ESLAW Warrants Hold Flat at $0.07 as Support and Resistance AlignInstitutional Buy Signals - vinanet.vn

Aug 15, 2026

Aug 14, 2026

ESLAW Warrant Holds at $0.07 as Estrella Immunopharma Trades FlatSystematic Flow - vinanet.vn

Aug 14, 2026

Estrella Immunopharma (ESLA): Armistice Capital discloses 4.99% ownership stake - Stock Titan

Aug 14, 2026

Aug 13, 2026

Estrella Immunopharma, Inc. 2Q 2026: Net loss $(2.31M), EPS $(0.05) — 10-Q Summary - TradingView

Aug 13, 2026

Tranche Update on Estrella Immunopharma, Inc.'s Equity Buyback Plan announced on January 30, 2024. - marketscreener.com

Aug 13, 2026

Aug 11, 2026

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - BioSpace

Aug 11, 2026